a Study to Evaluate the Safety and Efficacy of D-1553 Combined With IN10018 in KRAS G12C Mutant Solid Tumors
Status:
Recruiting
Trial end date:
2026-12-31
Target enrollment:
Participant gender:
Summary
This is a phase 1b/II, open-label study to evaluate the safety, tolerability,
pharmacokinetics and antitumor activities of D-1553 in combination with IN10018 in subjects
with locally advanced or metastatic solid tumor with KRAS G12C mutation.